#5-12E. Beyond Bone Density: Rethinking Osteogenesis Imperfecta Treatment (JAMA, 2026)

Does increasing bone mineral density (BMD) truly reduce fractures in osteogenesis imperfecta? This episode explores a multicenter, open-label randomized clinical trial investigating whether sequential therapy with teriparatide followed by zoledronic acid reduces fracture risk in adults compared to standard care. The study's key finding reveals that while the treatment significantly increased lumbar spine and total hip BMD, it failed to lower the incidence of new fractures. This suggests that diminished bone quality, rather than simply low bone mass, drives fracture pathogenesis. When critically appraising this trial, clinicians must note its open-label design, which inherently limits the objective interpretation of subjective patient-reported outcomes like quality of life and pain. For physician listeners, this paper is highly relevant as it signals a crucial paradigm shift: highlighting the urgent need to pivot therapeutic strategies from merely boosting bone density toward directly enhancing bone quality when managing osteogenesis imperfecta.

Citation: Hald JD, Ralston SH. Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial. Journal of the American Medical Association. 2026. DOI: 10.1001/jama.2026.6889

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.